In addition to the mechanism behind the rare form of thrombosis, the researchers say, they have also developed a diagnostic tool and a suggested therapy for “immediate clarification,” the German international broadcaster said on Friday.
The revelation came as European countries resumed dosing, developed by the British-Swedish drug company and the University of Oxford in the UK, after days of suspension due to fears of blood clots that caused deaths in some cases. .
Deutsche Welle reported the findings of researchers at the Greifswald teaching hospital in northern Germany, citing public broadcaster Norddeutscher Rundfunk.
The investigation showed how the vaccine caused rare brain thrombosis in a small number of patients, according to the report.
“The discovery means that targeted treatment can be offered to those who suffer from similar clotting, using a very common drug,” he said.
The success was the result of cooperation between Greifswald Hospital, the Paul Ehrlich Institute’s state health regulator and doctors in Austria.
The researchers pointed out that treatment will only be possible in patients with blood clots, rather than as a preventive treatment.
Symptoms such as continued headache, dizziness or visual disturbances lasting more than three days after vaccination require additional medical check-ups, the report said, citing a statement from the German Research Association for Thrombosis and Hemostasis.
Greifswald’s findings have not yet been published in a scientific journal and have therefore not been reviewed by independent experts. The Paul-Ehrlich Institute in Germany is now analyzing the work of scientists.